Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutical and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer.
Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.
The news comes after Veranova recently announced expansion – estimated at $30 million – of its antibody-drug conjugate (ADC) and highly potent compound development and manufacturing capabilities.
A seasoned commercial and business executive, Cécile brings a deep understanding of contract development and manufacturing organizations (CDMO) and the pharmaceutical industry. Her proven track record of building teams and transforming organizations and extensive experience across multiple drug modalities will ensure Cécile is an integral part of Veranova’s continued growth.
“I’m delighted to have Cécile join the Veranova team as our Chief Commercial Officer” said Mike Riley, Chief Executive Officer of Veranova. “Her expertise and track record in building and growing businesses will be invaluable as Veranova continues to execute our strategy to build a world-class CDMO.”
source: Chemanager-online.com
The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has established a partnership with Novo Nordisk Pharma Gulf focusing on the creation of a national scientific guide for obesity management and weight control. The collaboration also aims to enhance public awareness of cardiovascular diseases and their complications.
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. Under the deal, the companies will use Haya’s proprietary regulatory genome discovery platform to identify and validate long non-coding RNA (lncRNA) targets for developing potential treatments for obesity and related metabolic disorders.
The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.
